Released Presentations
PLENARY SESSIONS
 
FIRST PLENARY SESSION:
FINDING THE PATIENT IN HEALTH RESEARCH & POLICY
What Does "Patient-Centered Outcomes" Mean?
Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services, University of Washington, Seattle, WA, USA
Convergence or Divergence in Health Technology Assessment Do we need to choose?
Theresa Mullin, PhD, Director, Office of Planning and Informatics, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
FINDING THE PATIENT IN HEALTH RESEARCH & POLICY
Joe V. Selby, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

SECOND PLENARY SESSION:
FINDING THE PATIENT IN THE DRUG DEVELOPMENT PROCESS
Finding the Patient in the Drug Development Process: Regulatory Perspective
Laurie B. Burke, MPH, RPh, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
The Patient's Well-Being in the Development Process – BioPharma Perspective
Freda C. Lewis-Hall, MD, FAPA, Executive Vice President & Chief Medical Officer, Pfizer, Inc., New York, NY, USA
FINDING THE PATIENT IN THE DRUG DEVELOPMENT PROCESS
Gail Gibson Hunt, President & CEO, National Alliance for Caregiving, Bethesda, MD, USA

Third PLENARY SESSION:
ASSESSING THE EVIDENCE FOR THE HEALTH CARE DECISION MAKER
Overview of the Collaborative Initiative & an Introduction to Assessing the Evidence
Joseph C. Cappelleri, PhD, MS, MPH, Senior Director, Pfizer Inc., Groton, CT, USA
EVOLUTION OF TOOLS for ASSESSING THE EVIDENCE FOR HEALTH Care DECISIONS
Marc Berger, MD, VP Real World Data and Analytics, Pfizer, Inc., New York, NY, USA
ASSESSING Observational studies FOR HEALTH CARE DECISIONS & WHAT WE LEARNED FROM User Testing
Bradley Martin, PhD, Professor and Division Chair, University of Arkansas for Medical Sciences, College of Pharmacy, Department of Pharmacy Practice, Little Rock, AR, USA
ASSESSING NETWORK META ANALYSIS STUDIES FOR HEALTH CARE DECISIONs
Jeroen Jansen, PhD, Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA
Assessing Modeling Studies for Health Care Decisions
J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ, Canada
FUTURE DIRECTIONS
Marc Berger, MD, VP Real World Data and Analytics, Pfizer, Inc., New York, NY, USA
A payer Perspective
Sherry Andes, PharmD, Drug Intelligence Supervisor, Catamaran, Lisle, IL, USA
A Payer Perspective
Karen Worley, PhD, Research Leader, Comprehensive Health Insights, Humana, Inc., Cincinnati, OH, USA
Industry Perspective
Joseph C. Cappelleri, PhD, MS, MPH, Senior Director, Pfizer Inc., Groton, CT, USA
 
PODIUM AND POSTER PRESENTATIONS

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 18th Annual International Meeting, see: ISPOR Outcomes Research Digest an electronic database of over 22,000 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 18th Annual International Meeting – New Orleans, LA, USA
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
 
 WORKSHOP PRESENTATIONS

(Presentations to be added pending speaker approval)

W1: ECONOMETRIC METHODS FOR ASSESSING TREATMENT-EFFECT HETEROGENEITY
  COMBINING RANDOM FORESTS AND BAYESIAN GLM FOR ESTIMATION OF HETEROGENEOUS TREATMENT EFFECTS
David Vanness, PhD, Professor, Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA
W3: PRESENTING UNCERTAINTY (AND ITS CONSEQUENCES) IN COST EFFECTIVENESS TO BEST INFORM POLICY DECISIONS
  Presenting Uncertainty (and Its Consequences) in Cost-Effectiveness to Best Inform Policy Decision
Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
W4: CAPTURING PATIENT AND OBSERVER PERSPECTIVES FOR EVALUATING TREATMENTS FOR PEDIATRIC MENTAL HEALTH CONDITIONS - OPPORTUNITIES AND CHALLENGES
  How ADHD affects Data Quality/Collection
Keith Saylor, PhD, Licensed Clinical Psychologist, NeuroScience Inc., Herndon, PA, USA
Clinical Outcome Assessments (COAs) in the Evaluation of Treatment Benefit in Children
Elektra Papadopoulos, MD, MPH, Endpoints Reviewer, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
Concept Elicitation Interviews with Adolescents with ADHD
Asha Hareendran, PhD, MA Senior Research Scientist, United BioSource Corporation, London, United Kingdom
W5: ACCOUNTABLE CARE ORGANIZATION PHARMACEUTICAL READINESS: IS THE GLASS HALF-FULL, HALF-EMPTY, OR DO WE NEED A DIFFERENT GLASS?
  Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA; Marv Feldman, MS, RPh, Managing Principal, Consulting Services Group, Premier Inc., Charlotte, NC, USA; Eleanor Perfetto, MS, PhD, Senior Director, Reimbursement & Regulatory Affairs, Federal Government Relations, Pfizer, Inc., Washington, DC, USA
W6: BEST PRACTICES AND PROMISING MODELS FOR PATIENT ENGAGEMENT IN PATIENT-CENTERED RESEARCH
  Engaging Patients Throughout the Research Process
Sue Sheridan, MIM, MBA, Director of Patient Engagement, Patient-Centered Outcomes Research Institute, Washington, DC, USA
W9: ACCOUNTING FOR HETEROGENEITY, TEMPORAL UNCERTAINTY, AND IMPLEMENTATION IN UNCERTAINTY ASSESSMENT FOR HEALTH CARE DECISION-MAKING
  Uncertainty in Health Policy Decision- Making and the Expected Value of Implementation Strategies
Ties Hoomans, PhD, Assistant Professor, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
  Accounting for heterogeneity, temporal uncertainty, and implementation in uncertainty assessment for health care decision-making
Susan Griffin, PhD, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK
  Temporal Uncertainty in Health Care Decision-making
Ronan Mahon, MSc, PhD Student, Centre for Health Economics, University of York, York, North Yorkshire, UK
W10: VALUE-BASED PRICING: GETTING IT RIGHT FOR PEOPLE WITH CANCER
  VALUE-BASED PRICING: GETTING IT RIGHT FOR PEOPLE WITH CANCER
Jacque Anne Mallender, BA, MSc, Director, Matrix Knowledge, London, UK; Carole Anne Jones, MBA, Head of Pharmaceutical Advisory, Matrix Knowledge, London, UK; Alexis Wieroniey, BA (Hons), Senior Campaigns Officer, Prostate Cancer UK, London, UK
W11: MEASURING PATIENT REPORTED OUTCOMES IN RARE DISEASES
  MEASURING PATIENT REPORTED OUTCOMES IN RARE DISEASES
Katy Benjamin, PhD, Director, Patient Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Bethesda, MD, USA
  Measuring patient reported outcomes in rare diseases: challenges
Andrew J. Lloyd, DPhil, Vice President, Patient Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK
  PROs and Rare Diseases
Anne Pariser, MD, Associate Director for Rare Diseases, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA
  PROs in Rare Diseases
Rahul Sasane, PhD, Global Market Access Strategy Lead – Hematology, Bayer Pharmaceuticals, Montville, NJ, USA
W12: DISCRETE-CHOICE EXPERIMENTS AND BEST-WORST SCALING: EMPIRICAL AND METHODOLOGICAL DIFFERENCES AND DOES CHOICE MATTER?
  Joint Analysis of Best-Worst Scaling and Choice Data: Alzheimer's Caregiver Preferences for Treatment Outcomes
F. Reed Johnson, PhD, Distinguished Fellow & Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA
  The relevance of using patient preference elicitation methods in healthcare
Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada
  Discrete-choice experiments and best-worse scaling: empirical and methodological differences and does choice matter?
Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
W14: USING ELECTRONIC MEDICAL RECORD (EMR) DATA FOR CONDUCTING RETROSPECTIVE STUDIES: OPPORTUNITIES AND PITFALLS
  Using EMR data for conducting retrospective studies: Opportunities and Pitfalls
Natalia Olchanski, MS, Project Director, Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Pei-Jung Lin, PhD, Assistant Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Kathy Lang, PhD, Senior Director, Boston Health Economics, Inc., Waltham, MA, USA; Aaron Winn, MPP, Research Associate II, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
W18: ONE OF THESE PATIENTS IS NOT LIKE THE OTHERS: DEVELOPMENT AND APPLICATION OF A TOOL FOR HEALTH CARE DECISION MAKERS TO ASSESS AND CONSIDER HETEROGENEITY IN COVERAGE DECISIONS
  One of These Patients is Not Like The Others: Development and Application of a Tool for Health Care Decision Makers to Assess and Consider Heterogeneity in Coverage Decisions
Jennifer S. Graff, PharmD, Director, Comparative Effectiveness Research, National Pharmaceutical Council, Washington, DC, USA
W20: ACCOUNTING FOR HETEROGENEITY, TEMPORAL UNCERTAINTY, AND IMPLEMENTATION IN UNCERTAINTY ASSESSMENT FOR HEALTH CARE DECISION-MAKING
  Engaging patients as collaborators to improve health care planning, health service delivery and self-care
Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada
  Strategic Clinical Networks & the role of Patient Engagement Researchers
Tracy Wasylak, MSc, CHE, Vice President, Strategic Clinical Networks & Clinical Care Pathways, Alberta Health Services, Calgary, AB, Canada
  Patients as Partners in HTA
Durhane Wong-Reiger, PhD, Chair, International Alliance of Patients' Outcomes, Toronto, ON, Canada
  Patient Engagement Research as part of an emerging Science of Health Experience
Nancy J. Marlett, PhD, Associate Professor, Community Rehabilitation and Disability Studies Community Health Sciences, University of Calgary, Calgary, AB, Canada
W22: MODELS IN THE CLOUD - IMPROVING THE APPLICATION OF ECONOMIC MODELS WITH DYNAMIC DATA ANALYTICS AND A WEB-BASED GRAPHICAL USER INTERFACE
  Introduction
Cindy (Xin) Gao, PhD, Director, Health Economics, Pharmerit North America, LLC, Bethesda, MD, USA
  Technology Issues
Gijs Hubben, PhD, CEO, BaseCase Software, Berlin, Germany
  Case Study
Mei Xue, MBA, Senior Analyst, Pharmerit International, Bethesda, MD, USA
W24: NOVEL APPROACHES IN EARLY PLANNING FOR RELEVANT EVIDENCE GENERATION TO SUPPORT HEALTH CARE DECISION MAKING
  Novel Approaches in Early Planning for Relevant Evidence Generation to Support Health Care Decision Making
Jan E. Hansen, PhD, DrPH, Vice President, Global Health Outcomes, Allergan, Irvine, CA, USA
W26: EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
  EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA
Daniel M. Huse, MA, Vice President, Truven Health Analytics, Cambridge, MA, USA
  A CASE STUDY EXAMINING RISK FACTORS AND COSTS OF UNCONTROLLED HYPERTENSION
Emily Durden, PhD, Research Leader, Outcomes Research, Truven Health, Austin, TX, USA
  Demonstration Study of Healthcare Utilization by Obese Patients
Joseph Vasey, PhD, Director, Epidemiology, Integrated Analytic Services, Quintiles, Bellefonte, PA, USA
W27: EVALUATIONS OF TREATMENT PATHWAYS IN ONCOLOGY: CLINICAL AND ECONOMIC CONSIDERATIONS AND MODELING APPROACHES
  Use of Clinical Pathways in Oncology
Kevin Knopf, MD, MPH, Medical Oncologist, California Pacific Medical Center, San Francisco, CA, USA
  Evaluation of Treatment Pathways in Oncology: An Example in mCRPC
Sonja Sorensen, MPH, Senior Research Scientist, United BioSource Corporation, Bethesda, MD, USA
  Evaluation of Treatment Pathways in Oncology: Modeling Approaches
Feng Pan, PhD, Research Scientist, Health Economics, United BioSource Corporation, Bethesda, MD, USA
W28: ADAPTING AMCP FORMAT-BASED DOSSIERS: EVIDENCE GUIDELINES FOR SPECIALTY PHARMACEUTICALS, COMPANION DIAGNOSTICS, AND COMPARATIVE EFFECTIVENESS RESEARCH
  What's New in the AMCP Format 3.1 Specialty Pharmaceuticals
Jeff Lee, PharmD, National Director, Regional Scientific Services, Allergan. Inc., Franklin, TN, USA
  AMCP Format 3.1: Companion Diagnostics Addendum
David L. Veenstra, PhD, PharmD, Professor, Department of Pharmacy, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA
W29: DON'T FORGET ABOUT THE PATIENT! LISTENING TO PATIENTS AND INVOLVING THEM IN RESEARCH
  Advance Research by Working Directly with Patients
John Reites, BS, Director, Operations, Digital Patient Unit, Quintiles, Inc., Durham, NC, USA
W30: DEPLOYING EPRO INSTRUMENTS IN CLINICAL TRIALS: CHALLENGES AND SOLUTIONS
  Deploying ePRO Instruments in Clinical Trials: Challenges and Solutions
Tara Symonds, PhD, Senior Director, Outcomes Research, Pfizer, Inc., Kent, UK; Valdo Arnera, MD, General Manager, Europe, PHT Corporation, Geneva, Switzerland, Switzerland; J. Jason Lundy, PhD, Assistant Director, Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, USA; Cindy Howry, MS, Principal, ePRO Solutions, Bracket, Austin, TX, USA
W31: THE USE OF PATIENT-CENTERED HEALTH CARE INFORMATION FROM SOCIAL NETWORKING SOURCES IN HEALTH ECONOMICS AND OUTCOMES RESEARCH
  THE USE OF PATIENT-CENTERED HEALTH CARE INFORMATION FROM SOCIAL NETWORKING SOURCES IN HEALTH ECONOMICS AND OUTCOMES RESEARCH: An Example
Wendy Turenne, MS, VP Analytics, Healthrageous
  Considerations for the Inclusion of Social Networking/Social Media Data Sources into the Mix when Conducting HEOR Research
Luke Boulanger, MA, MBA, Senior Research Scientist / Senior Director, Health Economics, United BioSource Corporation, Lexington, MA, USA
 
ISSUE PANEL PRESENTATIONS

(Presentations to be added pending speaker approval)

IP1: ARE ADMINISTRATIVE CLAIMS DATA BECOMING OBSOLETE?
  Are Administrative Claims Data Becoming Obsolete?
Marc Berger, MD, Vice President, Real World Data & Analytics, Pfizer, Inc., New York, NY, USA
  Are Claims Data Becoming Obsolete?
William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
IP2: CAN A LIFE-EXTENDING DRUG BE COST-INEFFECTIVE EVEN IF OFFERED FOR FREE? THE CURIOUS ECONOMICS OF COSTS IN ADDED YEARS OF LIFE
Can A Life-Extending Drug Be Cost-Ineffective Even If Offered For Free? The Curious Economics Of Costs In Added Years Of Life
Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Cost of extending life: An industry perspective.
Mohan Bala, BS, Head, Oncology Market Access, Sanofi, Cambridge, MA, USA
  CAN A LIFE-EXTENDING DRUG BE COST-INEFFECTIVE EVEN IF OFFERED FOR FREE? THE CURIOUS ECONOMICS OF COSTS IN ADDED YEARS OF LIFE
Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
The curious economics of life-saving interventions: Costs in added years of life
Joshua T. Cohen, PhD, Associate Professor, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
IP3: HOW DO WE BALANCE PATIENT VALUE AND PAYER COST IN ONCOLOGY?
  Defining and measuring value in oncology
Darius Lakdawalla, PhD, Professor & Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, University of Southern California, Los Angeles, CA, USA
IP4: HOW CAN COMPARATIVE EFFECTIVENESS RESEARCH PLAY A MEANINGFUL ROLE IN ADDRESSING DISPARITIES IN HEALTH CARE? A MULTI-NATIONAL DIALOGUE
  HOW CAN COMPARATIVE EFFECTIVENESS RESEARCH CAN PLAY A MEANINGFUL ROLE IN ADDRESSING DISPARITIES IN HEALTH CARE? A MULTI-NATIONAL DIALOGUE
Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Services, Avalere Health LLC, Washington, DC, USA; Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA; Antony Morgan, MSc, PhD, FFPH, Associate Director, National Institute for Health and Clinical Excellence (NICE), London, UK; Bernd H. Brüggenjürgen, MD, MPH, Head, Institute for Health Economics, Steinbeis-University Berlin GmbH, and Vice Chairman, German Association for Health Sciences and Public (DVGPH), Berlin, Germany
IP5: RULES OF ENGAGEMENT IN DRUG DEVELOPMENT: ACTIVATING THE PATIENT VOICE (ISPOR Invited Issue Panel)
  RULES OF ENGAGEMENT IN DRUG DEVELOPMENT: ACTIVATING THE PATIENT VOICE
Eleanor M. Perfetto, PhD, MS, Senior Director, Reimbursement & Regulatory Affairs, Federal Government Relations, Pfizer, Inc., Washington, DC, USA
IP6: DO TRIAL DESIGN AND ENDPOINT SELECTION FOR TOMORROW'S CANCER DRUGS INCORPORATE PATIENT-CENTERED MEASURES AND MEET MULTIPLE STAKEHOLDER NEEDS?
  DO TRIAL DESIGN AND ENDPOINT SELECTION FOR TOMORROW'S CANCER DRUGS INCORPORATE PATIENT-CENTERED MEASURES AND MEET MULTIPLE STAKEHOLDER NEEDS?
Roy D. Baynes, MD, PhD, Senior Vice President, Oncology and Inflammation Therapeutics, Gilead Sciences Inc., Foster City, CA, USA
  MEETING MULTIPLE STAKEHOLDER NEEDS IN CANCER DRUG TRIAL DESIGN AND ENDPOINT SELECTION
Alexander Warren Bastian, MBA, Principal Consultant, GfK Bridgehead, San Francisco, CA, USA
  MEETING MULTIPLE STAKEHOLDER NEEDS IN CANCER DRUG TRIAL DESIGN AND ENDPOINT SELECTION: A Payer Proxy
Ron L. Akehurst, BSc, Professor of Health Economics, School of Health and Related Research, University of Sheffield, Sheffield, and Member, National Institute for Health and Clinical Excellence (NICE) Diagnostics Committee, Sheffield, UK
IP7: MODEL OR...ELSE? THE FUTURE OF ENHANCING THE GENERALISABILITY ACROSS LOCATIONS OF ECONOMIC EVALUATIONS
  Model or …Else? The future of enhancing the generalisability across locations of economic evaluation
Andrew Briggs, DPhil, MSc, William R. Lindsay Chair of Health Economics, Department of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
  Making Resource Allocation Decisions in Specific Jurisdictions: Models are Essential but Individual Patient Data are Desirable
Mark J. Sculpher, MSc, PhD
, Professor of Health Economics, Centre for Health Economics, University of York, Heslington,York, UK
  DECISION MAKING IN EMERGING MARKETS OF LATINOAMERICA: Requirements of local decision-makers for transferability of economic evaluations
Manuel Antonio Espinoza, MD, PhD, Lecturer, Department of Public Health, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
  The future of RCT-based economic evaluations: rational centre selection?
Adrian Gheorghe, MSc
, Doctoral Researcher, Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
IP8: CAN BAYESIAN ADAPTIVE CER TRIAL DESIGNS BRIDGE THE NEEDS OF PATIENTS, PAYERS, REGULATORS, AND MANUFACTURERS?
  CAN BAYESIAN ADAPTIVE CER TRIAL DESIGNS BRIDGE THE NEEDS OF PATIENTS, PAYERS, REGULATORS, AND MANUFACTURERS?
Jack Ishak, PhD, Director and Senior Research Scientist, Biostatistics and Epidemiology, United BioSource Corporation, Bethesda, MD, USA
IP9: WHEN SHOULD OBSERVATIONAL STUDIES BE USED FOR DECISION-MAKING, OR WHEN WILL THE EMPEROR HAVE CLOTHES?
  WHEN SHOULD OBSERVATIONAL STUDIES BE USED FOR DECISION-MAKING, OR WHEN WILL THE EMPEROR HAVE CLOTHES?
Robert W. Dubois, MD, PhD
, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA; Paul Wallace, MD, Senior Vice President and Director, Center for Comparative Effectiveness, The Lewin Group, Falls Church, VA, USA; Marcus Wilson, PharmD, President, HealthCore, Wilimington, DE, USA
  When should Observational Studies be used for Decision-making, or does the Emperor have no Clothes?
Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA
IP10: STAKEHOLDER ENGAGEMENT IN PATIENT-CENTERED OUTCOMES RESEARCH: HIGH TOUCH OR HIGH TECH?
  Stakeholder Engagement in Patient-Centered Outcomes Research: High Touch or High Tech?
Danielle Lavallee, PharmD, PhD, Lead Researcher & Senior Manager, Department of Surgery/Surgical Outcomes Research Center, University of Washington, Seattle, WA, USA; C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA; Paul Wicks, PhD, R&D Director, PatientsLikeMe, Cambridge, MA, USA; Rafael Alfonso, MD, PhD, Scientific Director, Surgical Outcomes Research Center, University of Washington, Seattle, WA, USA
IP11: WHOSE PERSPECTIVE SHOULD DETERMINE THE VALUE OF PERSONALIZED MEDICINE – THE PATIENT, THE PHYSICIAN OR SOCIETY?
  Whose perspective should determine the value of personalized medicine: the patient, physician or society
Maarten J IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands
  Same old same old. Why not real economic analysis?
F Reed Johnson, PhD, Principal economist, RTI Health Solutions, Research Triangle Park, NC, USA
  Patient preferences have important implications for determining the value of personalized medicine
Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada
  Personalized Medicine is Here Costs and Cost-Effectiveness are Important
Kathryn Phillips, PhD, Professor, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA
IP12: SETTING PRIORITIES IN RESEARCH: DOES VALUE OF INFORMATION ANALYSIS HAVE A ROLE?
  Informing decision makers using VOI methods
Susan Griffin, PhD
, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK
  Setting Priorities in Research: Does Value of Information Analysis Have a Role?
Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
IP13: PRESCRIPTION DRUG MONITORING PROGRAMS: ARE WE WALKING THE TIGHTROPE BETWEEN CONTROLLED SUBSTANCE ACCESS AND ABUSE?
  Prescription Drug Monitoring Programs: Are We Walking the Tightrope between Controlled Substance Access and Abuse?
Patricia R. Freeman, PhD, Clinical Associate Professor, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA
  Do PDMPs Restrict Access to Appropriate Treatment?
Bob Twillman, PhD, FAPM, Director of Policy and Advocacy, American Academy of Pain Management, Lenexa, KS, USA
  Do PDMPs Reduce Abuse and Diversion?
Cheryl Anderson, BSPharm, Director, South Carolina Prescription Monitoring Program and President, Alliance of States with Prescription Monitoring Programs, Bureau of Drug Control, South Carolina Department of Health and Environmental Control, Columbia, SC, USA
  Are PDMPs Safe and Effective? What is the Evidence?
Jeffery Talbert, PhD, Associate Professor & Director, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA
IP14: WHAT ARE THE EMERGING STANDARDS, BARRIERS, AND SOLUTIONS FOR PATIENT-REPORTED OUTCOMES IN PERFORMANCE EVALUATION AND QUALITY IMPROVEMENT?
  Patient-Reported Outcomes (PROs) in Performance Evaluation and Quality Improvement
Ethan Basch, MD, MSc
, Director, Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC, USA
  Can we use social media to support content validity of PRO instruments in medical product development
Ari Gnanaskathy, MSc MBA, Head, Patient Reported Outcomes, Patient Reported Outcomes, Novartis Pharmaceutical Corp, East Hanover, NJ, USA
  PROs in Performance Measurement
Karen Pace, PhD, MSN
, Senior Director, Performance Measures, National Quality Forum, Washington, DC, USA
  Patient Reported Outcomes: Examples of Measures in MN
Collette Pitzen, RN, BSN, CPHQ, Clinical Measure Development Manager, MN Community Measurement, Minneapolis, MN, USA
  Functional Status Assessment Measures using Patient-Reported Outcomes
Phyllis Torda, PhD
, Vice President of Strategic and Quality Solutions Group, National Committee for Quality Assurance (NCQA), Washington, DC, USA
IP15: DO TRIAL DESIGN AND ENDPOINT SELECTION FOR TOMORROW'S CANCER DRUGS INCORPORATE PATIENT-CENTERED MEASURES AND MEET MULTIPLE STAKEHOLDER NEEDS?
  CAN WE USE SOCIAL MEDIA TO SUPPORT CONTENT VALIDITY OF PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS IN MEDICAL PRODUCT DEVELOPMENT?
Margaret Rothman, PhD, Senior Director, Patient Reported Outcomes, Janssen, Washington, GA, USA
  CAN WE USE SOCIAL MEDIA TO SUPPORT CONTENT VALIDITY OF PATIENT REPORTED OUTCOME (PRO) INSTRUMENTS IN MEDICAL PRODUCT DEVELOPMENT?
Paul Wicks, PhD, R&D Director, PatientsLikeMe, Cambridge, MA, USA
ISPOR FORUMS
(Presentations to be added pending forum host approval)

CLINICIAN-REPORTED OUTCOMES (ClinROs): GOOD MEASUREMENT PRACTICES
Presented by the ISPOR Clinician-Reported Outcomes (ClinROs) Good Measurement Practices Task Force

ISPOR Patient Reported Outcomes Task Forces Clinician-Reported Outcomes Good Measurement Practices Task Force
John H. Powers, III, MD, FACP, FIDSA, Senior Medical Scientist, Support to Collaborative Clinical Research Branch (CCRB), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA

PRINCIPLES OF GOOD PRACTICE FOR BUDGET IMPACT ANALYSIS
Presented by the ISPOR Budget Impact Analysis Good Practices II Task Force

Updates and Changes to the Analytical Framework
J. Jaime Caro, MDCM, FRCPC, FACP, Senior Vice President, Research, United BioSource Corporation, Lexington, MA, USA, and Adjunct Professor of Medicine, Epidemiology & Biostatistics, McGill University, Montreal, PQ, Canada

Updates and Changes to the Data Sources and Inputs
Karen Lee, MA, Director, Health Economics, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada

Updates and Changes to the Reporting Methods
Mark Minchin, MBA, Technical Adviser – PASLU, National Institute for Health and Clinical Excellence, Manchester, UK

Other Issues
Josephine Mauskopf, PhD, Vice President of Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

Principles of good practice for budget impact analysis
Sean Sullivan, PhD, Stergachis Family Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS)
Presented by the ISPOR Health Economic Evaluation Publication Guidelines Task Force

CONSOLIDATED HEALTH ECONOMICS REPORTING STANDARDS - CHEERS: GOOD REPORTING PRACTICES
Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria; Andrew H. Briggs, MSc (York), MSc (Oxon), DPhil (Oxon), Associate Editor, Medical Decision Making, Co-Editor, Health Economics and William R Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Chris Carswell, MRPharmS, MSc, Editor, Pharmacoeconomics, Adis International, Auckland, New Zealand; Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

HEALTH TECHNOLOGY ACCESS AMONG THE BRICS COUNTRIES: BRAZIL, RUSSIA, INDIA, CHINA, AND SOUTH AFRICA
Presented by the ISPOR Brazil, Russia, India, China, and South Africa Regional Chapters

HEALTH TECHNOLOGY ACCESS AMONG THE BRICS COUNTRIES: BRAZIL, RUSSIA, INDIA, CHINA AND SOUTH AFRICA
Gabriela Tannus, MBA, MSc, President, ISPOR Brazil Chapter and Owner & Health Economics Director, Axia.Bio Consulting, Sao Paulo, Brazil

China's Efforts to Improve Access to Medicines
Wen Chen, PhD, President, ISPOR Shanghai Chapter, and Professor & Deputy Dean, School of Public Health, Fudan University, Shanghai, China

PRICING & REIMBURSEMENT AGAINST THE BACKGROUND OF HEALTHCARE REFORM IN RUSSIA
Vitaly V. Omelianovskiy, MD, PhD, President, ISPOR Russia HTA Chapter, Chairman of the Board, National Center for Technology Assessment in Health Care, and Deputy Director, Center for Monitoring and Clinical & Economic Evaluation, Moscow, Russia

ACCESS TO MEDICINES AND HEALTH TECHNOLOGIES IN INDIA: OPPORTUNITIES AND CHALLENGES
Madhur Gupta, MD, DM, Technical Officer, Pharmaceuticals, World Health Organization Country Office for India, New Delhi, India

Reimbursement Decision Making in South Africa
Jacques Snyman, MBChB, MPharm Med, MD, President, ISPOR South Africa Chapter and Clinical Pharmacologist, Agility Global Health Solutions, Pretoria, South Africa

HEALTH CARE DATA IN THE ARABIC-SPEAKING COUNTRIES: CHALLENGES IN COLLECTING, SHARING, AND APPLYING
Presented by the ISPOR Arabic Network

Health Care Data in Qatar
Daoud Al-Badriyeh, PhD, President, ISPOR Qatar Chapter, Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar

ISPOR Arabic Network Forum: Health Care Data in the Arabic - speaking Countries (UAE Perspective): Challenges in Collecting, Sharing, and Applying
Ola G. Al Ahdab Albannay, PhD, PGD, RPh, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

Health Care Data in the Arabic-speaking Countries: Challenges in Collecting, Sharing and Applying
Manal El-Hamamsy, BSPharm, PhD, Assistant Professor, Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt

HEALTH CARE DATA IN SAUDI ARABIA: CHALLENGES IN COLLECTING, SHARING, AND APPLYING
Mohammed Al-Kelya, PhD
, Head, Research Quality Management, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia; Abdulaziz Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, NGHA, Riyadh, Kingdom of Saudi Arabia

ECONOMIC ASSESSMENT IN AFRICA: DEVELOPMENT OF HEALTH ECONOMIC EVALUATION REPORTING
Presented by the ISPOR Egypt, Ghana, Nigeria and South Africa Regional Chapters

Economic Assessment in Africa: Development of Health Economic Evaluation Reporting Examples from: Egypt, Ghana, Nigeria and South Africa
Peter Agyei-Baffour, PhD, Health Economics Lecturer, Community Health Department, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

Health Economic Evaluation Reporting: The Vision of Orderliness in a Chaotic Environment
Anthony Waka Udezi, PhD, Department of Clinical Pharmacy, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

PRICING OF PHARMACEUTICALS IN EMERGING COUNTRIES OF THE CENTRAL AND EASTERN EUROPEAN REGION
Presented by the ISPOR Central & Eastern Europe Network

Pricing of Pharmaceuticals in Emerging Countries of the Central & Eastern European Region: The Case of POLAND
Joanna Lis, MSc, PhD, President, ISPOR Poland Chapter; Adjunct Professor, Pharmacoeconomics Department, Medical University of Warsaw; Director, Public Affairs and Market Access, Sanofi Poland, Warsaw, Poland

Pricing of Pharmaceuticals in Emerging Countries of the Central & Eastern European Region: The Case of Russia
Vitaly Omelianovskiy, MD, PhD, President, ISPOR HTA Russia Chapter and Professor & Chairman of the Board, National Center for Technology Assessment in Health Care; Deputy Director, Center for Monitoring and Clinical & Economic Evaluation Organization, National Center for Health Technology Assessment, Moscow, Russia

Pricing of Pharmaceuticals in Emerging Countries of the Central & Eastern European Region: The Case of Ukraine
Olga Zaliska, PhD, Dr.Sci (Pharm), President, ISPOR Ukraine Chapter and Professor, Department of Organization & Economy of Pharmacy and Medicine Technology, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PRICING OF PHARMACEUTICALS IN EMERGING COUNTRIES OF THE CENTRAL AND EASTERN EUROPEAN REGION
Zoltán Kaló, MD, MSc, PhD, Director, Health Economics Research Centre, Eötvös Loránd University (ELTE), Syreon Research Institute, Budapest, Hungary

MEET THE EDITORS OF VALUE IN HEALTH
Presented by the Co-Editors-in-Chief of Value in Health

Publishing in Value in Health What makes a Good Paper?
Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; C. Daniel Mullins, PhD, Co-Editor-in-Chief, Value in Health and Professor, Pharmaceutical Health Services Research Department, University of Maryland, Baltimore, MD, USA

MARKET ACCESS CHALLENGES FOR IN VITRO DIAGNOSTIC: SIMILARITIES AND DIFFERENCES BETWEEN THE US AND EUROPEAN MARKETS
Presented by the ISPOR HTA Special Interest Group

Introduction: Diagnostic Reimbursement and HTA in the US and Europe
Susan Garfield, DrPH, Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA

Payer perspectives and actions impacting diagnostics in the US and Europe
Eric Faulkner, MPH, Director, Global Market Access, Quintiles, Durham, NC, USA

The Unintended Consequences of Addressing Molecular Pathology Stacking Codes
Michael Longacre, BSc, Reimbursement Director, Corporate/ Shared Services, Becton Dickenson, Washington, DC, USA

Real world examples of HTA and payer actions impacting diagnostics in Europe
Nick Poulios, PhD, Head, Medical Outcomes – Reimbursement & Economics, Roche Molecular Systems, Pleasanton, CA, USA

USING MIXED MODES TO CAPTURE PATIENT-REPORTED OUTCOMES DATA IN CLINICAL TRIALS
Presented by the ISPOR PRO Mixed Modes Good Research Practices Task Force

Data Collection Modes and Migration between Modes
Stephen Joel Coons, PhD, MS, MEd, Director, Patient-Reported Outcomes Consortium, Critical Path Institute, Tucson, AZ, USA

Mixing Modes of Patient-Reported Outcomes Data Collection in Clinical Trials: Recommendations
Sonya Eremenco, MA, Chair, ISPOR PRO Task Force: Good Research Practices for Mixed Modes to Collect PRO Data in Clinical Trials and ePRO Manager, United BioSource Corporation, Bethesda, MD, USA

EDUCATIONAL SYMPOSIA

(Presentations to be added pending symposia host approval)

OLD WINE IN NEW BOTTLES: DO COMPARATIVE EFFECTIVENESS AND PATIENT-CENTERED OUTCOMES RESEARCH REPRESENT A NEW PARADIGM IN HEALTH RESEARCH?
(Sponsored by ICON)

Mark J. Sculpher, MSc, PhD, Senior Scientific Advisor, Oxford Outcomes, an ICON plc company and Professor of Health Economics, Centre for Health Economics, University of York, York, UK

PROPOSERS: COMPARATIVE EFFECTIVENESS AND PATIENT-CENTERED OUTCOMES RESEARCH DO REPRESENT A NEW PARADIGM IN HEALTH RESEARCH

Richard J. Willke, PhD, Lead, Center for Health Economics, Epidemiology, and HTA, Global Market Access, Primary Care Business Unit, Pfizer, Inc., Peapack, NJ, USA

OPPOSERS: COMPARATIVE EFFECTIVENESS AND PATIENT-CENTERED OUTCOMES RESEARCH DO NOT REPRESENT A NEW PARADIGM IN HEALTH RESEARCH

Sean D. Sullivan, BScPharm, PhD, Stergachis Family Professor of Pharmacy and Public Health, Director, Pharmaceutical Outcomes Research and Policy Program, and Associate Dean for Research, School of Pharmacy, University of Washington, Seattle, WA, USA

Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA


MULTI CRITERIA DECISIONMAKING IN AMERICA: SEA CHANGE OR NATURAL EVOLUTION?
(Sponsored by LASER ANALYTICA)

MULTI-CRITERIA DECISION ANALYSIS: BASIC PRINCIPLES
Jim Dolan, MD, Professor, Department of Public Health Sciences, University of Rochester Medical Center, Rochester, NY, USA

MULTICRITERIA ACROSS THE HEALTHCARE CONTINUUM: TOOLS AND APPLICATIONS
Mireille Goetghebeur, PhD, MEng, Vice President, Scientific LA-SER and Adjunct Professor, University of Montreal, Montreal, QC, Canada


ASSESSING THE EVIDENCE FOR BETTER PATIENT CARE: SYNTHESIZING THE BODY OF EVIDENCE – A TOOL FOR FORMULARY DECISION MAKING
(Sponsored by the National Pharmaceutical Council)


Willingness to Pay, Ability to Pay, and Money-Equivalent Benefit:  Measuring And Using Monetized Health Benefits
(Sponsored by RTI Health Solutions)


The Promise of Personalized Medicine: "Getting it Right the First Time"
(Sponsored by Xcenda)


FAST ACCESS TO BIG NATIONAL HEALTH CARE DATA SETS
(Sponsored by CPRD)

THE PATIENT AND PUBLIC PERSPECTIVE ON DATA FOR RESEARCH
Simon Denegri, National Director for Public Participation and Engagement in Research, NIHR, London, UK

Drugs in Hospital – A New Key Dataset
Josh Hiller, Principal, IMS Health, London, UK

UK DATA - THE VIEW FROM THE UNITED STATES
Carrie McAdam Marx, PhD, RPh, Research Assistant Professor, Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah, USA

Using EHR records to identify patients for interventional studies
Tim Williams PhD, Head of Research, CPRD, London, UK

 

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.